9. The use according to any one of claims 1 to 7, wherein the inflammatory disorder is arthritis or an autoimmune disease.

10. The use according to claim 9, wherein the arthritis is selected from the group consisting of acute arthritis, osteoarthritis, and rheumatoid arthritis.

11. The use according to any one of claims 1 to 10, wherein the adipose tissue-derived cell suspension is from subcutaneous adipose tissue.

12. A pharmaceutical composition which comprises:

(i) an adipose tissue-derived cell suspension which comprises adipocytes and adipose-derived non-adipocyte cells; or

(ii) a cell-free extract which is prepared from an adipose tissue-derived cell suspension, wherein the adipose tissue-derived cell suspension comprises adipocytes and adipose-derived non-adipocyte cells, and wherein the cell-free extract comprises cell-derived molecules which are released from the cells following cell death or the break-up of the adipose tissue cells and/or the secretions of cells of the adipose tissue-derived cell suspension;

together with a pharmaceutically-acceptable carrier or diluent.

13. A method of generating an adipose tissue-derived cell suspension which comprises adipocytes and adipose-derived non-adipocyte cells from a sample of adipose tissue from a mammal, the method comprising:

dissociating the sample of adipose tissue to form a suspension of cells which comprises adipocytes and adipose-derived non-adipocyte cells;